FOG Pharmaceuticals, Inc.
In October 2016, Deerfield invested in FOG Pharmaceuticals, Inc. through its Series A preferred stock. FOG is an early-stage biotechnology company developing next-generation peptide inhibitors which target traditionally ‘undruggable’ intracellular protein-protein interactions.
The platform is based on 1) stitching technology which locks small alpha helixies in a ridged structure and 2) cyclic peptides which enable oral delivery of an amino acid based drug. The platform can be applied to many different targets and the lead program is targeting beta catenin, which plays a key role in the pathogenesis of cancer.